Synapse - Howard Scher

Results (1133)

Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations

Meeting Abstract

Abida, W.; Bryce, A. H.; Vogelzang, N. J.; Amato, R. J.; Percent, I.; Shapiro, J. D.; McDermott, R.; Hussain, A.; Patnaik, A.; Petrylak, D.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

Use of nuclear-localized androgen receptor splice variant 7 protein in CTCs after 1st androgen receptor signaling inhibitor (ARSi) as a predictive biomarker for overall survival on a second ARSi or taxane chemotherapy in metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Scher, H. I.; Graf, R. P.; Hulling, M.; Carbone, E.; Dittamore, R.
Annals of Oncology (2018)

Fulltext@MSK | Save

Overall survival (OS) implications for patients with mCRPC through coverage and adoption of nuclear AR-V7 testing by healthcare systems

Meeting Abstract

Hornberger, J.; Graf, R. P.; Hulling, M.; Attard, G.; Allan, A.; Dittamore, R.; Scher, H. I.
Annals of Oncology (2018)

Fulltext@MSK | Save

TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician's choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)

Meeting Abstract

Ryan, C. J.; Abida, W.; Bryce, A. H.; Balar, A. V.; Dumbadze, I.; Given, R. W.; Morris, D.; Petrylak, D. P.; Redfern, C. H.; Scher, H. I.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Validation of nuclear-localized AR-V7 on circulating tumor cells (CTC) as a treatment-selection biomarker for managing metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Scher, H. I.; Graf, R. P.; Schreiber, N. A.; Winquist, E.; McLaughlin, B.; Lu, D.; Orr, S.; Fleisher, M.; Lowes, L.; Anderson, A. K. L.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

c15-153: Randomized phase IB/II study of enzalutamide with and without ribociclib in patients with metastatic castrate resistant, chemotherapy naive prostate cancer that retains RB expression

Meeting Abstract

Kelly, W. K.; Godwin, J. L.; Hoffman-Censits, J. H.; Knudsen, K. E.; De Leeuw, R.; Leiby, B. E.; Southwell, T.; Hubert, C.; Smith, D. C.; Chatta, G. S.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Consensus statement on circulating biomarkers for advanced prostate cancer

Meeting Abstract

Sumanasuriya, S.; Omlin, A. G.; Armstrong, A. J.; Attard, G.; Chi, K. N.; Bevan, C. L.; Waugh, D. J.; Ijzerman, M. J.; De Laere, B.; Lolkema, M. P.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

TRITON2: An international, multicenter, open-label, phase II study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)

Meeting Abstract

Abida, W.; Bryce, A. H.; Balar, A. V.; Chatta, G. S.; Dawson, N. A.; Guancial, E. A.; Hussain, A.; Jha, G. G.; Lipsitz, D. U.; Patnaik, A.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Consensus on molecular imaging and theranostics in prostate cancer

Journal Article

Fanti, S.; Minozzi, S.; Antoch, G.; Banks, I.; Briganti, A.; Carrio, I.; Chiti, A.; Clarke, N.; Eiber, M.; De Bono, J.; more...
Lancet Oncology (2018)

Fulltext@MSK | Save

Lessons from the SWITCH trial: Changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC)

Journal Article

Teo, M. Y.; Scher, H. I.
British Journal of Cancer (2018)

Fulltext@MSK | Save